NCT01110317View on ClinicalTrials.gov

A Study of Paliperidone Blood Concentrations in Patients With Schizophrenia After Administration of Paliperidone Palmitate

PHASE1CompletedINTERVENTIONAL
Enrollment

49

Participants

Timeline

Start Date

July 31, 2005

Study Completion Date

March 31, 2006

Conditions
Schizophrenia
Interventions
DRUG

paliperidone palmitate 100 mg

Patients will receive a single paliperidone palmitate 100 mg equivalent injection in the gluteal or deltoid muscle on Day 1, 8, 36, and 64.

All Listed Sponsors
lead

Johnson & Johnson Pharmaceutical Research & Development, L.L.C.

INDUSTRY

NCT01110317 - A Study of Paliperidone Blood Concentrations in Patients With Schizophrenia After Administration of Paliperidone Palmitate | Biotech Hunter | Biotech Hunter